KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Leases: 2011-2024

Historic Current Leases for Nektar Therapeutics (NKTR) over the last 11 years, with Dec 2024 value amounting to $19.9 million.

  • Nektar Therapeutics' Current Leases rose 3.16% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 3.16%. This contributed to the annual value of $19.9 million for FY2024, which is 3.16% up from last year.
  • As of FY2024, Nektar Therapeutics' Current Leases stood at $19.9 million, which was up 3.16% from $19.3 million recorded in FY2023.
  • Nektar Therapeutics' Current Leases' 5-year high stood at $19.9 million during FY2024, with a 5-year trough of $13.9 million in FY2020.
  • In the last 3 years, Nektar Therapeutics' Current Leases had a median value of $19.3 million in 2023 and averaged $19.3 million.
  • Data for Nektar Therapeutics' Current Leases shows a peak YoY rose of 25.34% (in 2021) over the last 5 years.
  • Nektar Therapeutics' Current Leases (Yearly) stood at $13.9 million in 2020, then grew by 25.34% to $17.4 million in 2021, then grew by 7.03% to $18.7 million in 2022, then climbed by 3.17% to $19.3 million in 2023, then increased by 3.16% to $19.9 million in 2024.